Duality Biotherapeutics (HKSE:09606) Net Margin %: -418.34% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09606 Duality Biotherapeutics Inc HKSE:09606
9 GF Score
Price HK$178.50
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Net Margin %?

Duality Biotherapeutics HKSE:09606 -1.05% 9 Net Margin % is -418.34% as of Jun. 2026. GuruFocus rates HKSE:09606 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 949 Biotechnology companies, Duality Biotherapeutics ranks worse than 59.54% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Duality Biotherapeutics's Net Income for the six months ended in Jun. 2026 was HK$-1,046.0 Mil. Duality Biotherapeutics's Revenue for the six months ended in Jun. 2026 was HK$250.0 Mil. Therefore, Duality Biotherapeutics's net margin for the quarter that ended in Jun. 2026 was -418.34%.

The historical rank and industry rank for Duality Biotherapeutics's Net Margin % or its related term are showing as below:

HKSE:09606' s Net Margin % Range Over the Past 10 Years
Min: -24189.65   Med: -97.12   Max: -20.01
Current: -173.82

HKSE:09606's Net Margin % is ranked worse than
59.54% of 949 companies
in the Biotechnology industry
Industry Median: -77.58 vs HKSE:09606: -173.82

Duality Biotherapeutics  (HKSE:09606) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Duality Biotherapeutics Net Margin % Related Terms

Duality Biotherapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Net Margin % Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Margin %
-24,193.13 -20.01 -54.11 -140.13

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Net Margin % -168.75 -83.65 -418.34

HKSE:09606 vs VRTX, REGN, MRNA: Net Margin % Comparison

For the Biotechnology subindustry, Duality Biotherapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Duality Biotherapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Duality Biotherapeutics's Net Margin % falls into.


HKSE:09606
9GF Score
Duality Biotherapeutics Inc HKSE:09606
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Duality Biotherapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2814.1505244821/2008.2498838851
=-140.13 %

Duality Biotherapeutics's Net Margin for the quarter that ended in Jun. 2026 is calculated as

Net Margin=Net Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-1045.982703239/250.03175462937
=-418.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -418.34% mean?
Duality Biotherapeutics (HKSE:09606) has a Net Margin % of -418.34% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Duality Biotherapeutics and its competitors. According to the industry distribution chart, Duality Biotherapeutics ranks #565 out of 949 companies in the Biotechnology industry, placing it in the top 59.5%.
Is Duality Biotherapeutics' Net Margin % too high?
Duality Biotherapeutics' current Net Margin % is -418.34%. Based on the distribution chart, Duality Biotherapeutics ranks #565 out of 949 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Duality Biotherapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #565 out of 949 companies for Net Margin %. This places Duality Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Net Margin % is -418.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (HKSE:09606) has a current Net Margin % of -418.34%. The current Net Margin % is -418.34%. Duality Biotherapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Duality Biotherapeutics (HKSE:09606), the current Net Margin % is -418.34% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 4ZB:Germany
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
9GF Score

Get the complete analysis for HKSE:09606

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$178.50
Price